Latest Pharmaceuticals News

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Cardiex reported strong growth in its Pulse arterial health monitor sales during Q4 FY25, surpassing A$0.7 million for the year and advancing its transition to subscription-based digital health services.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.